Eleven Biotherapeutics Inc., a Cambridge biopharmaceutical company, said Tuesday that it has secured $20 million dollars in Series A equity financing, expanding the total Series A investment to $45 million.
New investor, JAFCO Co. Ltd., a Tokyo-based private equity firm, joined the Series A financing with a $10 million investment; $10 million was also received from commitments from existing investors, Third Rock Ventures and Flagship Ventures, which helped found the company in 2010, Eleven Biotherapeutics said in a press release.
Third Rock of Boston and Flagship of Cambridge are venture capital firms with a focus on the life sciences industry.
Part of the proceeds from the financing will be used to advance Eleven’s first drug candidate, known as EBI-005, into clinical development later this year. The drug is designed to treat dry-eye syndrome.
Chris Reidy can be reached at firstname.lastname@example.org.